FACT SHEET

Tumor organoids

Patient-derived models for the next-gen drug discovery and development

Reduce oncology drug attrition rates

Predict patient response before moving your drug to the clinic

HUB Organoids are unique patient-derived in vitro models developed directly from patient biopsies or resections. Our living tumor biobank includes:

• genetically stable organoid models
• a wide range of carcinoma indications
• matched primary tumor and healthy tissue-derived organoids
• organoids derived from both primary and metastatic lesions

Using HUB´s drug screening platform, clinically-relevant data can be generated that allows you to identify new targets, refine your drug combination strategies, or stratify your patient population with confidence.